133 related articles for article (PubMed ID: 37977148)
21. Multidrug resistance in relapsed acute myeloid leukemia: evidence of biological heterogeneity.
Patel C; Stenke L; Varma S; Lindberg ML; Björkholm M; Sjöberg J; Viktorsson K; Lewensohn R; Landgren O; Gottesman MM; Gillet JP
Cancer; 2013 Aug; 119(16):3076-83. PubMed ID: 23674237
[TBL] [Abstract][Full Text] [Related]
22. Precise single-cell transcriptomic mapping of normal and leukemic cell states reveals unconventional lineage priming in acute myeloid leukemia.
Zeng AGX; Iacobucci I; Shah S; Mitchell A; Wong G; Bansal S; Gao Q; Kim H; Kennedy JA; Minden MD; Haferlach T; Mullighan CG; Dick JE
bioRxiv; 2023 Dec; ():. PubMed ID: 38234771
[TBL] [Abstract][Full Text] [Related]
23. Olutasidenib: a novel mutant IDH1 inhibitor for the treatment of relapsed or refractory acute myeloid leukemia.
Cortes JE
Expert Rev Hematol; 2024 Jun; 17(6):211-221. PubMed ID: 38747392
[TBL] [Abstract][Full Text] [Related]
24. Transcriptome-based molecular subtypes and differentiation hierarchies improve the classification framework of acute myeloid leukemia.
Cheng WY; Li JF; Zhu YM; Lin XJ; Wen LJ; Zhang F; Zhang YL; Zhao M; Fang H; Wang SY; Lin XJ; Qiao N; Yin W; Zhang JN; Dai YT; Jiang L; Sun XJ; Xu Y; Zhang TT; Chen SN; Zhu HH; Chen Z; Jin J; Wu DP; Shen Y; Chen SJ
Proc Natl Acad Sci U S A; 2022 Dec; 119(49):e2211429119. PubMed ID: 36442087
[TBL] [Abstract][Full Text] [Related]
25.
Höllein A; Meggendorfer M; Dicker F; Jeromin S; Nadarajah N; Kern W; Haferlach C; Haferlach T
Blood Adv; 2018 Nov; 2(22):3118-3125. PubMed ID: 30455361
[TBL] [Abstract][Full Text] [Related]
26. Genetic aberrations involved in relapse of pediatric acute myeloid leukemia: A literature review.
Zafar N; Ghias K; Fadoo Z
Asia Pac J Clin Oncol; 2021 Oct; 17(5):e135-e141. PubMed ID: 32573082
[TBL] [Abstract][Full Text] [Related]
27. A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia.
Zeng AGX; Bansal S; Jin L; Mitchell A; Chen WC; Abbas HA; Chan-Seng-Yue M; Voisin V; van Galen P; Tierens A; Cheok M; Preudhomme C; Dombret H; Daver N; Futreal PA; Minden MD; Kennedy JA; Wang JCY; Dick JE
Nat Med; 2022 Jun; 28(6):1212-1223. PubMed ID: 35618837
[TBL] [Abstract][Full Text] [Related]
28. Biological and therapeutic implications of a unique subtype of NPM1 mutated AML.
Mer AS; Heath EM; Madani Tonekaboni SA; Dogan-Artun N; Nair SK; Murison A; Garcia-Prat L; Shlush L; Hurren R; Voisin V; Bader GD; Nislow C; Rantalainen M; Lehmann S; Gower M; Guidos CJ; Lupien M; Dick JE; Minden MD; Schimmer AD; Haibe-Kains B
Nat Commun; 2021 Feb; 12(1):1054. PubMed ID: 33594052
[TBL] [Abstract][Full Text] [Related]
29. RUNX1 mutation associated with clonal evolution in relapsed pediatric acute myeloid leukemia with t(16;21)(p11;q22).
Ismael O; Shimada A; Elmahdi S; Elshazley M; Muramatsu H; Hama A; Takahashi Y; Yamada M; Yamashita Y; Horide K; Kojima S
Int J Hematol; 2014 Feb; 99(2):169-74. PubMed ID: 24374719
[TBL] [Abstract][Full Text] [Related]
30. Double and single mixed-lineage leukemia-rearranged subclones in pediatric acute myeloid leukemia: a case report.
McGrath M; Smink G
J Med Case Rep; 2021 May; 15(1):228. PubMed ID: 33957966
[TBL] [Abstract][Full Text] [Related]
31. Single-cell analysis reveals altered tumor microenvironments of relapse- and remission-associated pediatric acute myeloid leukemia.
Mumme H; Thomas BE; Bhasin SS; Krishnan U; Dwivedi B; Perumalla P; Sarkar D; Ulukaya GB; Sabnis HS; Park SI; DeRyckere D; Raikar SS; Pauly M; Summers RJ; Castellino SM; Wechsler DS; Porter CC; Graham DK; Bhasin M
Nat Commun; 2023 Oct; 14(1):6209. PubMed ID: 37798266
[TBL] [Abstract][Full Text] [Related]
32. Uncovering the Genomic Landscape in Newly Diagnosed and Relapsed Pediatric Cytogenetically Normal FLT3-ITD AML.
Buelow DR; Pounds SB; Wang YD; Shi L; Li Y; Finkelstein D; Shurtleff S; Neale G; Inaba H; Ribeiro RC; Palumbo R; Garrison D; Orwick SJ; Blachly JS; Kroll K; Byrd JC; Gruber TA; Rubnitz JE; Baker SD
Clin Transl Sci; 2019 Nov; 12(6):641-647. PubMed ID: 31350825
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of chromosomal abnormalities at relapse in children with relapsed acute myeloid leukemia: A retrospective cohort study of the Relapsed AML 2001/01 Study.
Klein K; Beverloo HB; Zimmermann M; Raimondi SC; von Neuhoff C; de Haas V; van Weelderen R; Cloos J; Abrahamsson J; Bertrand Y; Dworzak M; Fynn A; Gibson B; Ha SY; Harrison CJ; Hasle H; Elitzur S; Leverger G; Maschan A; Razzouk B; Reinhardt D; Rizzari C; Smisek P; Creutzig U; Kaspers GJL
Pediatr Blood Cancer; 2022 Jan; 69(1):e29341. PubMed ID: 34532968
[TBL] [Abstract][Full Text] [Related]
34. Defining the transcriptional control of pediatric AML highlights RARA as a superenhancer-regulated druggable dependency.
Perez MW; Sias-Garcia O; Daramola A; Wei H; Terrell M; Rashid R; Park WD; Duong K; Horton TM; Li F; Cherayil N; Koren JV; Gant VU; Junco JJ; Curry CV; Stevens AM; Lin CY; Yi JS
Blood Adv; 2021 Dec; 5(23):4864-4876. PubMed ID: 34543389
[TBL] [Abstract][Full Text] [Related]
35. Clonal evolution of acute myeloid leukemia from diagnosis to relapse.
Vosberg S; Greif PA
Genes Chromosomes Cancer; 2019 Dec; 58(12):839-849. PubMed ID: 31478278
[TBL] [Abstract][Full Text] [Related]
36. Outcome of Intensive Therapy for Children with Relapsed Acute Myeloid Leukemia: A Single Institution Korean Study.
Lee JW; Yoo JW; Kim S; Jang PS; Chung NG; Cho B
Cancer Res Treat; 2022 Oct; 54(4):1230-1239. PubMed ID: 34922415
[TBL] [Abstract][Full Text] [Related]
37. [Current diagnosis and treatment for pediatric acute myeloid leukemia].
Shiba N
Rinsho Ketsueki; 2017; 58(4):389-399. PubMed ID: 28484171
[TBL] [Abstract][Full Text] [Related]
38. Paired single-B-cell transcriptomics and receptor sequencing reveal activation states and clonal signatures that characterize B cells in acute myeloid leukemia.
Guo S; Mohan GS; Wang B; Li T; Daver N; Zhao Y; Reville PK; Hao D; Abbas HA
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38418394
[TBL] [Abstract][Full Text] [Related]
39. Transcriptome analysis offers a comprehensive illustration of the genetic background of pediatric acute myeloid leukemia.
Shiba N; Yoshida K; Hara Y; Yamato G; Shiraishi Y; Matsuo H; Okuno Y; Chiba K; Tanaka H; Kaburagi T; Takeuchi M; Ohki K; Sanada M; Okubo J; Tomizawa D; Taki T; Shimada A; Sotomatsu M; Horibe K; Taga T; Adachi S; Tawa A; Miyano S; Ogawa S; Hayashi Y
Blood Adv; 2019 Oct; 3(20):3157-3169. PubMed ID: 31648321
[TBL] [Abstract][Full Text] [Related]
40. Blast cells surviving acute myeloid leukemia induction therapy are in cycle with a signature of FOXM1 activity.
Williams MS; Basma NJ; Amaral FMR; Wiseman DH; Somervaille TCP
BMC Cancer; 2021 Oct; 21(1):1153. PubMed ID: 34711181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
